Noah Goodman
Known title: Chief Business OfficerCIK: 0002060075
Associated companies
Transaction History
| KYMR | ▼ Sell | Open Market | 3,389 | $387K | 7/1/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 2,500 | $273K | 6/25/2026 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 5,000 | $105K | 6/25/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 2,500 | $298K | 6/25/2026 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 2,500 | $53K | 6/22/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 2,500 | $248K | 6/22/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 1,347 | $121K | 4/14/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 2,000 | $175K | 4/10/2026 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 2,500 | $53K | 4/9/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 2,670 | $233K | 4/9/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 2,500 | $223K | 4/9/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 3,094 | $268K | 4/9/2026 | View on chart |
| KYMR | ▲ Buy | Grant | 9,225 | $0 | 3/2/2026 | View on chart |
| KYMR | ▲ Buy | Grant | 50,000 | $0 | 4/8/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Raymond James initiates coverage on Kymera with Outperform rating
Raymond James has started covering Kymera Therapeutics, assigning an Outperform rating and a price target of $140. This new analyst note adds to the current consensus, which has an average target of $139.35 from 23 analysts. Recent discussions also question whether the company's pipeline is over-hyped or developing into a major therapeutic success.
Raymond James initiates coverage on Kymera with Outperform rating. Raymond James has started covering Kymera Therapeutics, assigning an Outperform rating and a price target of $140. This new analyst note adds to the current consensus, which has an average target of $139.35 from 23 analysts. Recent discussions also question whether the company's pipeline is over-hyped or developing into a major therapeutic success.